http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010066912-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3ca021f2871bd6355d556ce7075fdee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f11ef5c5a12fee064e3e2571990d30ff |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-203 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-25 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| filingDate | 2009-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abd14332d79dfd61178a9519ca6f85cb |
| publicationDate | 2010-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2010066912-A3 |
| titleOfInvention | Compounds having activity in correcting mutant cftr cellular processing |
| abstract | The present invention relates to a compound which is characterized by the formula (I) or a pharmaceutically acceptable salt, solvate, hydrate thereof, wherein the ring systems A and B are independently selected from a monosaccharide, aryl (preferably phenyl), a heteroaryl or cycloalkyl (preferably cyclohexan), preferably with all substituents in equatorial configurations; R1 is independently selected from alkyl (preferably C1 to C6), a substituted or unsubstituted phenyl, preferably CH3; R2 is H, alkyl (preferably C1 to C6), a carbohydrate in a glycosidic β-linkage, preferably H; R3, R4, R5, and R6 are independently selected from H, (OH) hydroxy, alkyl preferably C1 to C6, alkoxy (preferably C1 to C6), amino, alkylamino (preferably C1 to C6), halogen, benzylamino, or benzoylamino; X is O, NH, alkylamino (NR), CO, S; and Y is O, NH, alkylamino (NR), CO, S. The present invention also relates to the compound of the invention and, optionally, a pharmaceutically acceptable carrier, for use in the treatment of (for treating) and/or preventing a disease or medical condition which is associated with mutant CFTR. |
| priorityDate | 2008-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.